[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C@@H1][Branch1][=Branch2][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][=C][C][=Branch1][C][=O][N][Branch1][Branch2][C][=Branch1][C][=O][N][Ring1][Branch2][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022."}]